Terumo EBIT

The latest EBIT for TRUMF is $150B as of June 2026. That compares with $190B in the prior-year period — down 18.1% year over year. That is above the Healthcare sector average of $110B. Investors often review this figure alongside Terumo's historical trend and sector peers before judging valuation or financial health.

Over the past year, TRUMF's EBIT moved from $190B to $150B — a 18.1% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Terumo's operating scale or balance-sheet position.

Against Healthcare companies, TRUMF currently prints $150B for EBIT, while the sector average sits near $110B. That is roughly 43.0% above the sector mean. Large gaps often invite a closer look at Terumo's growth, margins, and balance sheet.

A EBIT figure of $150B for TRUMF is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.

After noting TRUMF's EBIT ($150B), review year-over-year change from $190B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.